norfloxacin has been researched along with enoxacin in 195 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 92 (47.18) | 18.7374 |
| 1990's | 46 (23.59) | 18.2507 |
| 2000's | 27 (13.85) | 29.6817 |
| 2010's | 29 (14.87) | 24.3611 |
| 2020's | 1 (0.51) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, Y; Jinbo, Y; Kawahata, Y; Kondo, H; Sakamoto, F; Taguchi, M; Tsukamoto, G | 1 |
| Bouzard, D; Di Cesare, P; Essiz, M; Jacquet, JP; Masuyoshi, M; Oki, T; Remuzon, P; Weber, A | 1 |
| Domagala, JM; Hanna, LD; Heifetz, CL; Hutt, MP; Mich, TF; Sanchez, JP; Solomon, M | 1 |
| Domagala, JM; Heifetz, CL; Mich, TF; Nichols, JB | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Antón-Fos, GM; Duart, MJ; Mut-Ronda, S; Salabert-Salvador, MT | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Beikmohammadi, L; Emami, S; Faramarzi, MA; Foroumadi, A; Ghodsi, S; Najjari, S; Samadi, N; Shafiee, A; Shirazi, FH | 1 |
| Long, F; Rouquette-Loughlin, C; Shafer, WM; Yu, EW | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Hashida, Y; Konaka, R; Kourai, H; Maseda, H; Shirai, A | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gotoh, N; Hayashi, N; Okuda, J; Wakahara, Y | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Ba, Y; Hou, X; Wang, S; Xu, Z; Yang, H; Zhang, J | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Hannan, A | 1 |
| Arai, S; Gohara, Y; Kawashima, T; Kuwano, K; Matsu-Ura, I | 1 |
| Jones, RN | 1 |
| Kiyota, H; Mitani, H | 1 |
| Erwin, ME; Jones, RN | 1 |
| Hoshino, K; Saiki, A; Sawai, T; Yamaguchi, A | 1 |
| Kudo, M; Ohkubo, T; Sugawara, K | 1 |
| Jiang, SC; Zhang, YY; Zhun, BY | 1 |
| Chuah, SK; Mandal, AK; Thadepalli, CD; Thadepalli, H | 1 |
| Furusawa, M; Iino, T; Marumoto, Y; Nozaki-Renard, J; Ohta, G; Sato, Y | 1 |
| Jiang, SC; Wang, XF; Wei, YL | 1 |
| Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H | 1 |
| Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B | 1 |
| Barnett, G; Carbó, M; de la Torre, R; Segura, J | 1 |
| Guzelian, PS; Hunt, C; Karnes, HT; Polk, RE; Sarkar, M | 1 |
| Nakanishi, S; Okuno, H | 1 |
| Matsumoto, F; Morita, M; Takahashi, T | 1 |
| Bhattacharya, SS; Lal, HM; Lalitha, MK; Nisha, AK; Ramamoorthy, U | 1 |
| Aubert, G; Denis, M; Dorche, G; Loboguerrero, M; Lucht, F; Puech, C | 1 |
| Dopp, C; Naumann, P | 1 |
| Goto, M; Kawakatsu, K; Sano, M; Takeyama, M; Yamamoto, I; Yamashina, H | 1 |
| Kashimoto, S; Kojima, T; Kouno, K; Kurobe, N; Minami, A; Nakamura, S; Nakata, K; Ohue, T; Sakaguchi, Y; Yoshida, H | 1 |
| Shah, PM | 2 |
| Harder, S; Papenburg, A; Staib, AH; Stille, W | 1 |
| Bia, FJ; Divo, AA; Patton, CL; Sartorelli, AC | 1 |
| Beer, C; Harder, S; Papenburg, A; Shah, PM; Staib, AH; Stille, W | 1 |
| Neu, HC | 3 |
| Appleman, ME; Gaines, JK; Hadfield, TL; Winn, RE | 1 |
| Hooper, DC; Wolfson, JS | 1 |
| Guimaraes, MA; Noone, P | 1 |
| Baur, C; Davies, BI; Maesen, FP; Teengs, JP | 2 |
| Edlund, C; Nord, CE | 2 |
| Bailey, J; Heppleston, C; Richmond, SJ | 1 |
| Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC | 1 |
| Smith, SM | 1 |
| Avesani, V; Delmee, M | 1 |
| Felmingham, D; Grüneberg, RN; O'Hare, MD; Ridgway, GL | 2 |
| Cremer, AW; Felmingham, D; Grüneberg, RN; O'Hare, MD; Ridgway, GL; Robbins, MJ; Wall, RA; Williams, AH | 1 |
| Baltch, AL; Bassey, CM; Smith, RP | 1 |
| Barry, AL; Jones, RN; Thornsberry, C | 1 |
| Grimm, H | 2 |
| Høiby, N | 1 |
| Just, G; Shah, PM; Stille, W; Weigand, G | 1 |
| Cohen, SP; Hooper, DC; Levy, SB; McMurry, LM; Souza, KS; Wolfson, JS | 1 |
| Weinstein, MP | 1 |
| Davies, S; Sparham, PD; Spencer, RC | 1 |
| Berlin, OG; Bruckner, DA; Young, LS | 1 |
| Kudoh, Y; Matsushita, S; Ohashi, M; Yamada, S | 1 |
| Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
| Verbist, L | 1 |
| Greenwood, D; Muranaka, K | 1 |
| Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N | 1 |
| Bebear, C; de Barbeyrac, B; Quentin, C; Renaudin, H | 1 |
| Kresken, M; Wiedemann, B | 1 |
| Bremner, DA; Dickie, AS; Singh, KP | 1 |
| Fernandes, PB; Swanson, RN | 1 |
| Baars, B; Cullmann, W; Opferkuch, W; Stieglitz, M | 1 |
| Traub, WH | 2 |
| Campbell, ME; Clarke, AM; Zemcov, SJ | 1 |
| Cowlishaw, A; Eley, A; Greenwood, D; Slater, G; Teoh-Chan, CH | 1 |
| de Moor, G; Lacroix, G; Mambour, A; Rossion, N; Schuyteneer, F; van der Auwera, P | 1 |
| Bailey, J; Heppleston, C; Richmond, S | 1 |
| Bryskier, A; Devos, J; Dubreuil, L; Romond, C | 1 |
| Kurata, T; Okazaki, O; Tachizawa, H | 1 |
| Chin, NX; Neu, HC; Novelli, A | 1 |
| Goto, M; Kawakatsu, K; Ohkita, C; Sano, M; Takeyama, M; Yamamoto, I; Yamashina, H | 1 |
| Asakawa, M; Yasumoto, R | 1 |
| Cattier, B; Gavignet, M; Goudeau, A; Koubaa, N; Quentin, R | 1 |
| Petrou, MA; Rogers, TR | 1 |
| Walker, RC; Wright, AJ | 1 |
| Andrews, JM; Griggs, D; Lister, D; McNulty, CA; Wise, R | 2 |
| Rietbrock, N; Staib, AH | 1 |
| King, A; Phillips, I | 1 |
| Dabbs, DJ; Limb, DI; Spencer, RC | 1 |
| Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Thornsberry, C | 1 |
| Floyd-Reising, SA; Hindler, JA; Kelley, SG; Young, LS | 1 |
| Arpi, M; Bentzon, MW; Gahrn-Hansen, B; Søgaard, P | 1 |
| Barry, AL; Jones, RN | 2 |
| Smith, CR | 1 |
| Edlund, C; Kager, L; Lidbeck, A; Nord, CE | 1 |
| Baars, AM; van Herwaarden, CL; Vree, TB; Wijnands, WJ | 1 |
| Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R | 1 |
| Dørflinger, T; Gasser, TC; Graversen, PH; Larsen, EH | 1 |
| Akalin, E; Baykal, M | 1 |
| Hashimoto, J; Miyake, K; Nagai, T; Takaba, H; Yamamoto, M | 1 |
| Smith, JT | 1 |
| Eggleston, M; Park, SY | 1 |
| Kumada, T; Neu, HC | 1 |
| Bauer, D; Häberle, R; Traub, WH | 1 |
| Chartrand, SA; Marks, MI; Scribner, RK; Weber, AH; Welch, DF | 1 |
| Kashimoto, S; Katae, H; Minami, A; Nakamura, S; Nakata, K; Shimizu, M; Takase, Y; Yamagishi, J | 1 |
| Kashimoto, S; Kurobe, N; Nakamura, S; Ohue, T; Shimizu, M; Takase, Y | 1 |
| Inoue, M; Kouno, K; Mitsuhashi, S | 1 |
| Chin, NX; Neu, HC | 1 |
| Koornhof, HJ; Saunders, J; Shrire, L; Traynor, R | 1 |
| Bauernfeind, A; Ullmann, U | 1 |
| Adhami, ZN; Lockley, R; Webberly, M; Wise, R | 1 |
| Elezoglou, V; Kounenis, G; Koutsoviti-Papadopoulou, M | 1 |
| Decaris, B; Vandewiele, D; Volff, JN | 1 |
| Fujita, H; Matsuo, I | 1 |
| Cho, JK; Han, HJ; Kim, JH; Kim, K; Lee, DS; Park, WB | 1 |
| Iakovlev, VP | 1 |
| Griffiths, NM; Hirst, BH; Simmons, NL | 1 |
| Phillips, I; Power, EG | 1 |
| Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M | 1 |
| Aarons, L; Davis, JD; Houston, JB | 1 |
| Hale, JA; Knapp, JS; Neal, SW; Rice, RJ; Whittington, WL; Wintersheid, K | 1 |
| Kaatz, GW; Seo, SM | 2 |
| Hostacká, A | 2 |
| Fujii, T; Miyazaki, H; Mizuki, Y; Ohmori, H; Yamaguchi, T; Yamamoto, K | 1 |
| Akahane, K; Fukuda, H; Ito, Y; Kimura, Y; Miyasaka, T | 1 |
| Hostacká, A; Majtán, V | 1 |
| Chen, CH; Chiang, HY; Lee, F; Lee, JH; Lee, SH; Liu, YT; Tsou, TL; Wang, TM | 1 |
| Asanuma, A; Iga, T; Kawakami, J; Sawada, Y; Yamamoto, K; Yanagisawa, K | 1 |
| Kinzig-Schippers, M; Naber, KG; Sörgel, F; Well, M | 1 |
| Feng, S; Jiang, S; Wang, X | 1 |
| Barbosa, J; Bergés, R; Sanz-Nebot, V | 1 |
| Chignell, CF; Martínez, L | 1 |
| Albini, A; Fasani, E; Profumo, A | 1 |
| Candura, SM; D'Agostino, G; Di Nucci, A; Fiori, E; Ricotti, P; Spelta, V; Tagliani, M; Tonini, M | 1 |
| Aizawa, M; Fukuda, H; Ishige, K; Ito, Y | 1 |
| Majtán, V; Majtánová, L | 1 |
| Clark, DW; Layton, D; Pearce, GL; Shakir, SA; Wilton, LV | 1 |
| Brewer, PD; Buxton, TB; Farcasiu, D; Hartmann, JF; Herczegh, P; Kovács-Kulyassa, A; McPherson, JC; Plowman, KM; Stroebel, GG; Sztaricskai, F | 1 |
| Aquilini, D; Bartoloni, A; Paradisi, F | 1 |
| Schaeffer, AJ | 1 |
| Fukuda, H; Kawamura, Y | 1 |
| Monti, S; Sortino, S | 1 |
| Chen, L; Huang, JM; Ye, FQ | 1 |
| Ono, C; Tanaka, M | 1 |
| Foroumadi, A; Kiani, Z; Mansouri, S; Rahmani, A | 1 |
| Chiang, CH; Lu, DW; Tai, MC | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Espinosa-Mansilla, A; Gómez, DG; Peña, AM; Salinas, F | 1 |
| Depta, JP; Pichler, WJ; Schmid, DA | 1 |
| Romero, IC; Saravia, NG; Walker, J | 1 |
| Antoniadou-Vyza, E; Michaleas, S | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Allen, NS; Lorenzo, F; Navaratnam, S | 1 |
| Cárdenas, YM; Chavez, V; Cordero, T; Fernández, A; Fuentes, A; Hincapie, L; Izzo, C; López, V; Ramirez, AH; Vargas, F; Zoltan, T | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Homma, M; Kobayashi, D; Kobayashi, T; Kohda, Y; Momo, K | 1 |
| Chang, C; Chen, T; Li, J; Liu, F; Lu, X; Niwa, O; Wang, Q; Xue, Q; Zhou, T | 1 |
12 review(s) available for norfloxacin and enoxacin
| Article | Year |
|---|---|
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration Rate; Half-Life; Humans; Kidney Failure, Chronic; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1990 |
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Topics: Anti-Bacterial Agents; Bacteria; Blood Proteins; Ciprofloxacin; Enoxacin; Fluorine; Humans; Kidney; Kinetics; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Protein Binding; Quinolines; Urinary Tract Infections | 1985 |
A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
Topics: Ciprofloxacin; Enoxacin; Humans; Intestines; Naphthyridines; Norfloxacin; Ofloxacin; Oropharynx; Oxazines; Pefloxacin; Quinolines | 1988 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Female; Humans; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1987 |
Quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Enoxacin; Humans; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; Ciprofloxacin; Enoxacin; Humans; Imipenem; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Thienamycins | 1987 |
Review of the 4-quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Enoxacin; Humans; Kinetics; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1987 |
[Pharmacokinetics of fluoroquinolones].
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Humans; Norfloxacin; Ofloxacin; Pefloxacin | 1993 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
2 trial(s) available for norfloxacin and enoxacin
| Article | Year |
|---|---|
[Clinical evaluation of enoxacin].
Topics: Adult; Dysentery, Bacillary; Enoxacin; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Norfloxacin; Respiratory Tract Infections; Typhoid Fever; Urinary Tract Infections | 1991 |
4-quinolones inhibit biotransformation of caffeine.
Topics: Adult; Biotransformation; Caffeine; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Interactions; Enoxacin; Humans; Male; Molecular Structure; Norfloxacin; Ofloxacin; Pipemidic Acid; Quinolones; Random Allocation; Theophylline | 1988 |
181 other study(ies) available for norfloxacin and enoxacin
| Article | Year |
|---|---|
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
Topics: Animals; Anti-Infective Agents; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1992 |
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Chemical Phenomena; Chemistry; Dogs; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Staphylococcus; Structure-Activity Relationship | 1989 |
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
Topics: Anti-Bacterial Agents; Bacteria; DNA, Bacterial; DNA, Superhelical; Escherichia coli; Microbial Sensitivity Tests; Naphthyridines; Plasmids; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
Topics: Animals; Anti-Bacterial Agents; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Discriminant Analysis; Drug Design; Microbial Sensitivity Tests; Quantitative Structure-Activity Relationship; Quinolones | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; In Vitro Techniques; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2006 |
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
Topics: Anti-Bacterial Agents; Antiporters; ATP-Binding Cassette Transporters; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Ethidium; Fluorescence Polarization; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Norfloxacin | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cetylpyridinium; Disinfectants; Drug Resistance, Multiple, Bacterial; Membrane Proteins; Mutation; Norfloxacin; Quaternary Ammonium Compounds; Serratia marcescens | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Fluoroquinolones; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Vibrio cholerae O1 | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Comparative in vitro activity of enoxacin and other fluoroquinolones against multi-resistant strains of Salmonella typhi.
Topics: Ampicillin; Anti-Infective Agents; Chloramphenicol; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin; Quinolones; Salmonella typhi; Species Specificity; Trimethoprim, Sulfamethoxazole Drug Combination; Typhoid Fever | 1992 |
[In vitro antimicrobial activities of new quinolone antibiotics against Mycoplasma pneumoniae].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Macrolides; Mycoplasma pneumoniae; Norfloxacin; Ofloxacin; Quinolones; Tetracyclines | 1992 |
In vitro evaluation of E-4695, a new fluoro-naphthyridine.
Topics: Anti-Bacterial Agents; Azetidines; Bacteria; Ciprofloxacin; Drug Evaluation, Preclinical; Enoxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Quinolones | 1992 |
[Influence of new quinolones on superoxide anion generation of polymorphonuclear leukocytes].
Topics: Ciprofloxacin; Enoxacin; Humans; In Vitro Techniques; Neutrophils; Norfloxacin; Ofloxacin; Superoxides | 1992 |
In vitro activity of CP-74667 compared with four other fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Enoxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones | 1992 |
OmpF channel permeability of quinolones and their comparison with beta-lactams.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Cell Membrane Permeability; Cephalosporins; Diffusion; Enoxacin; Escherichia coli; Liposomes; Nalidixic Acid; Norfloxacin; Ofloxacin; Stereoisomerism | 1992 |
Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Humans; Hydrogen-Ion Concentration; Norfloxacin; Ofloxacin; Spectrophotometry, Ultraviolet | 1992 |
Antimicrobial activity of intravenous quinolones on the intestinal microflora in dogs.
Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Colony Count, Microbial; Dogs; Enoxacin; Escherichia coli; Feces; Injections, Intravenous; Jejunum; Norfloxacin; Streptococcus | 1991 |
Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity.
Topics: Acquired Immunodeficiency Syndrome; Cell Line; Cell Survival; Ciprofloxacin; Enoxacin; HIV-1; Humans; Lymphocytes; Norfloxacin; Ofloxacin | 1990 |
[Effect of fluoroquinolones made in China in the treatment of acute bacillary dysentery. A report of 212 cases].
Topics: Acute Disease; Dysentery, Bacillary; Enoxacin; Humans; Microbial Sensitivity Tests; Norfloxacin; Shigella sonnei | 1990 |
Quinolone pharmacokinetics and metabolism.
Topics: Administration, Oral; Anti-Infective Agents; Biological Availability; Biotransformation; Ciprofloxacin; Enoxacin; Fleroxacin; Half-Life; Humans; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin | 1990 |
Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.
Topics: Caffeine; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Male; Models, Biological; Norfloxacin; Ofloxacin; Pipemidic Acid; Quinolones | 1990 |
In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Hydroxylation; Microsomes, Liver; Norfloxacin; Theophylline; Uric Acid; Xanthines | 1990 |
Comparison of inhibitory effects of new quinolones on drug metabolizing activity in the liver.
Topics: Acetaminophen; Animals; Anti-Infective Agents; Enoxacin; Glutathione; Liver; Liver Function Tests; Male; Microsomes, Liver; Mixed Function Oxygenases; Norfloxacin; Ofloxacin; Rats; Theophylline | 1990 |
[Therapeutic drug monitoring of fluoroquinolone].
Topics: Anti-Infective Agents; Bile; Biological Assay; Biological Availability; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Quinolones; Sputum | 1990 |
Susceptibility pattern of bacterial isolates to lomefloxacin.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Nalidixic Acid; Norfloxacin; Quinolones | 1990 |
[Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enoxacin; Escherichia coli; Fleroxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Pefloxacin; Pseudomonas aeruginosa; Serratia marcescens | 1989 |
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Norfloxacin; Ofloxacin | 1989 |
Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.
Topics: Adult; Drug Interactions; Enoxacin; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Theophylline | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Lung Diseases; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Skin Diseases, Infectious; Urinary Tract Infections | 1989 |
The role of quinolones in staphylococcal infection.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Humans; Norfloxacin; Ofloxacin; Pefloxacin; Staphylococcal Infections | 1989 |
[Gyrase inhibitors modify metabolising processes in the liver].
Topics: Caffeine; Ciprofloxacin; DNA Topoisomerases, Type II; Enoxacin; Humans; Liver; Male; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pipemidic Acid; Topoisomerase II Inhibitors | 1987 |
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro.
Topics: Aminocoumarins; Animals; Anti-Infective Agents; Chloroquine; Ciprofloxacin; Coumarins; Drug Interactions; Drug Resistance; Enoxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Oxolinic Acid; Pefloxacin; Plasmodium falciparum; Tetracycline; Topoisomerase II Inhibitors | 1988 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Osteomyelitis; Oxazines; Pefloxacin; Quinolines; Respiratory Tract Infections; Sexually Transmitted Diseases; Surgical Wound Infection; Urinary Tract Infections | 1987 |
Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
Topics: Anti-Bacterial Agents; Bordetella pertussis; Cinoxacin; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Whooping Cough | 1987 |
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Topics: Acinetobacter; Bacteria; Bacterial Infections; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enoxacin; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pseudomonas aeruginosa; Quinolines; Serratia; Staphylococcus | 1986 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Naphthyridines; Neisseria; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Pneumococcal Infections; Pseudomonas Infections; Quinolines; Streptococcus pneumoniae | 1986 |
Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; Ciprofloxacin; Clostridium; Enoxacin; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1986 |
The action of quinolone carboxylic acids on Chlamydia trachomatis in vitro.
Topics: Animals; Carboxylic Acids; Cells, Cultured; Chlamydia trachomatis; Ciprofloxacin; Enoxacin; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1986 |
In-vitro activity of newer quinolones against aerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Calcium; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Magnesium Sulfate; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Pseudomonas; Quinolines; Sulfates; Zinc; Zinc Sulfate | 1986 |
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Penicillin Resistance; Piperazines; Quinolines; Staphylococcus aureus | 1986 |
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Clostridium; Enoxacin; Fluoroquinolones; Humans; Infant, Newborn; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1986 |
The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
Topics: 4-Quinolones; Aeromonas; Anti-Bacterial Agents; Anti-Infective Agents; Campylobacter fetus; Cinoxacin; Ciprofloxacin; Diarrhea; Enoxacin; Fluoroquinolones; Humans; In Vitro Techniques; Intestines; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Oxolinic Acid; Pefloxacin; Pipemidic Acid; Quinolines; Quinolizines; Quinolones; Salmonella; Shigella; Vibrio cholerae; Vibrio parahaemolyticus; Yersinia enterocolitica | 1985 |
The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
Topics: 4-Quinolones; Anti-Infective Agents; Cinoxacin; Ciprofloxacin; Enoxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Oxolinic Acid; Pefloxacin; Pipemidic Acid; Quinolines; Quinolizines; Quinolones; Streptococcus pneumoniae | 1985 |
Comparative in vitro studies with 4-quinolone antimicrobials.
Topics: 4-Quinolones; Anti-Infective Agents; Bacteria; Cinoxacin; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Oxolinic Acid; Pefloxacin; Pipemidic Acid; Quinolines; Quinolizines; Quinolones | 1985 |
Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pseudomonas aeruginosa; Quinolines | 1986 |
In vitro evaluation of A-56619 and A-56620, two new quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Piperazines; Quinolines | 1986 |
[In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
Topics: Anti-Bacterial Agents; Cinoxacin; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Gram-Negative Aerobic Bacteria; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pipemidic Acid; Pseudomonas aeruginosa; Quinolines; Topoisomerase II Inhibitors | 1985 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Humans; Male; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Topoisomerase II Inhibitors | 1986 |
[Resistance against new gyrase inhibitors--1985/86].
Topics: Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Topoisomerase II Inhibitors | 1987 |
Endogenous active efflux of norfloxacin in susceptible Escherichia coli.
Topics: Anti-Infective Agents; Biological Transport, Active; Cell Membrane; Cell Membrane Permeability; Ciprofloxacin; Enoxacin; Escherichia coli; Kinetics; Norfloxacin; Ofloxacin; Spheroplasts | 1988 |
Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.
Topics: Anti-Bacterial Agents; Bacteria; Cefotaxime; Ceftazidime; Enoxacin; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Norfloxacin; Quinolones; Sepsis; Tobramycin | 1988 |
[In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
Topics: Acinetobacter; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Gram-Negative Bacteria; Immunodiffusion; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pipemidic Acid; Pseudomonas | 1986 |
Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Enoxacin; Mycobacterium; Mycobacterium avium; Mycobacterium bovis; Mycobacterium tuberculosis; Naphthyridines; Nontuberculous Mycobacteria; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1987 |
[In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
Topics: Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Vibrio cholerae | 1987 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines | 1987 |
The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Enoxacin; Enterococcus faecalis; Humans; Naphthyridines; Nephelometry and Turbidimetry; Norfloxacin; Urinary Bladder | 1988 |
[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Microbial; Enoxacin; Female; Humans; Male; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Peptides, Cyclic; Pipemidic Acid; Rifampin; Tetracycline; Tetracycline Resistance; Urinary Tract Infections; Vancomycin; Virginiamycin | 1988 |
[In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
Topics: 4-Quinolones; Anti-Bacterial Agents; Ciprofloxacin; Enoxacin; Humans; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Mycoplasmataceae; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Quinolones; Ureaplasma | 1988 |
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Enterobacteriaceae; Enterococcus faecalis; Humans; Nalidixic Acid; Norfloxacin; Ofloxacin; Pseudomonas aeruginosa; Staphylococcus aureus | 1988 |
In-vitro activity of fleroxacin compared with three other quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin | 1988 |
Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1988 |
Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
Topics: Acinetobacter; Ampicillin; Anti-Bacterial Agents; Bacteria; Cefotaxime; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Enterococcus faecalis; Gentamicins; Haemophilus influenzae; Mezlocillin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Penicillin Resistance; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus | 1985 |
Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Pipemidic Acid; Quinolines; Serratia marcescens | 1985 |
In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Enoxacin; Gentamicins; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pefloxacin | 1985 |
Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Drug Evaluation; Enoxacin; Humans; Hydrogen-Ion Concentration; Models, Biological; Nalidixic Acid; Naphthyridines; Norfloxacin; Urinary Bladder; Urinary Tract Infections | 1985 |
In vitro activity of enoxacin compared with norfloxacin and amikacin.
Topics: Amikacin; Anti-Bacterial Agents; Bacteria; Calcium; Drug Interactions; Drug Resistance, Microbial; Enoxacin; Enterobacteriaceae; Enterococcus faecalis; Kanamycin; Magnesium; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pseudomonas aeruginosa; Staphylococcus aureus | 1985 |
Antichlamydial activity of quinolone carboxylic acids.
Topics: Chlamydia trachomatis; Ciprofloxacin; Enoxacin; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1985 |
[Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
Topics: Bacteria, Anaerobic; Bacteroides; Clostridium; Enoxacin; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1985 |
Effect of new quinolones on drug-metabolizing enzyme system of rat hepatic microsomes.
Topics: Animals; Anti-Bacterial Agents; Cytochrome P-450 Enzyme System; Enoxacin; Male; Microsomes, Liver; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Rats; Rats, Inbred Strains | 1988 |
In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Magnesium; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines; Quinolones | 1988 |
Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.
Topics: 17-Hydroxycorticosteroids; Adult; Aminophylline; Enoxacin; Female; Humans; Hydrocortisone; Male; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Theophylline | 1988 |
[Comparison of enoxacin, ofloxacin, and norfloxacin concentration in human benign prostatic tissue].
Topics: Administration, Oral; Enoxacin; Humans; Male; Norfloxacin; Ofloxacin; Prostate; Tissue Distribution | 1988 |
In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Enoxacin; Female; Genital Diseases, Female; Genital Diseases, Male; Haemophilus; Haemophilus Infections; Haemophilus influenzae; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1988 |
In-vitro activity of antifungal agents in combination with four quinolones.
Topics: 4-Quinolones; Amphotericin B; Anti-Infective Agents; Antifungal Agents; Candida; Candida albicans; Ciprofloxacin; Drug Combinations; Enoxacin; Flucytosine; Mepartricin; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolines; Saccharomyces cerevisiae | 1988 |
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Half-Life; Humans; Kinetics; Male; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Tissue Distribution | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Male; Middle Aged; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1986 |
[Gyrase inhibitors: unwanted central nervous system effects].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Brain Chemistry; Brain Diseases; Ciprofloxacin; Enoxacin; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Solubility | 1987 |
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pefloxacin; Quinolines | 1986 |
The comparative pharmacokinetics of five quinolones.
Topics: Administration, Oral; Adult; Ciprofloxacin; Enoxacin; Half-Life; Humans; Infusions, Intravenous; Kinetics; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1986 |
In-vitro selection of bacteria resistant to the 4-quinolone agents.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Staphylococcus; Streptococcus | 1987 |
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines; Regression Analysis | 1987 |
In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Quinolines; Vancomycin | 1987 |
Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enoxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1987 |
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
The adverse effects of fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
Comparative effects of enoxacin and norfloxacin on human colonic microflora.
Topics: Adult; Bacteria; Clostridium; Colon; Enoxacin; Enterobacteriaceae; Female; Humans; Male; Middle Aged; Naphthyridines; Norfloxacin | 1987 |
Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Enoxacin; Female; Humans; Male; Middle Aged; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Theophylline | 1987 |
Comparative pharmacokinetics of new quinolones.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Enoxacin; Humans; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
Quinolone penetration into canine vaginal and urethral secretions.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Dogs; Enoxacin; Female; Fluoroquinolones; Mucous Membrane; Naphthyridines; Norfloxacin; Quinolines; Urethra; Vagina | 1987 |
[Fluoroquinolones].
Topics: Bacteria; Chemical Phenomena; Chemistry; Ciprofloxacin; Enoxacin; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1987 |
Comparison of enoxacin and norfloxacin in patients with cystitis.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacteria; Cystitis; Drug Resistance, Microbial; Enoxacin; Female; Humans; Male; Middle Aged; Naphthyridines; Norfloxacin | 1987 |
Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
Topics: 4-Quinolones; Anti-Bacterial Agents; Cinoxacin; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Escherichia coli; Fluoroquinolones; Mutation; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Oxolinic Acid; Pipemidic Acid; Quinolines; Quinolizines; Quinolones | 1986 |
The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines; Quinolones; Structure-Activity Relationship; Urinary Tract Infections | 1985 |
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mutation; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines | 1985 |
Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
Topics: Blood Bactericidal Activity; Ciprofloxacin; Culture Media; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Phagocytosis; Pipemidic Acid; Quinolines; Serratia marcescens; Topoisomerase II Inhibitors | 1984 |
Characterization of two clinical, multiple-drug-resistant isolates of Enterobacter cloacae.
Topics: Adult; Animals; Anti-Bacterial Agents; Antigens, Bacterial; Bacteriocins; Blood Bactericidal Activity; Cephalosporinase; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Microbial; Electrophoresis, Agar Gel; Enoxacin; Enterobacter; Enterobacteriaceae; Female; Humans; Male; Mice; Nalidixic Acid; Naphthyridines; Norfloxacin; O Antigens; R Factors; Virulence | 1984 |
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Stability; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pseudomonas | 1983 |
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Enoxacin; Gentamicins; Male; Mice; Nalidixic Acid; Naphthyridines; Norfloxacin; Pipemidic Acid | 1983 |
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Autoradiography; Bile; Dogs; Enoxacin; Female; Kinetics; Macaca fascicularis; Male; Mice; Nalidixic Acid; Naphthyridines; Norfloxacin; Protein Binding; Rats; Rats, Inbred Strains; Species Specificity; Tissue Distribution | 1983 |
In vitro and in vivo antibacterial activity of AT-2266.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin; Male; Mice; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Naphthyridines; Norfloxacin; Pipemidic Acid | 1983 |
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Colony-Forming Units Assay; Drug Resistance, Microbial; Drug Synergism; Enoxacin; Microbial Sensitivity Tests; Mutagens; Nalidixic Acid; Naphthyridines; Norfloxacin; Pseudomonas aeruginosa; Trimethoprim | 1983 |
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
Topics: Anti-Bacterial Agents; Bacteria; Cinoxacin; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Enterobacteriaceae; Nalidixic Acid; Naphthyridines; Norfloxacin; Oxolinic Acid; Pseudomonas aeruginosa; Quinolines | 1984 |
A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolines; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1984 |
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Topics: Bacteria; Bacterial Infections; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines | 1984 |
The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
Topics: Adult; Body Fluids; Enoxacin; Half-Life; Humans; Kinetics; Male; Nalidixic Acid; Naphthyridines; Norfloxacin; Tissue Distribution | 1984 |
Inhibitory effect of flumequine, enoxacin and norfloxacin on the GABA-induced contractile effect on the guinea pig ileum.
Topics: Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Enoxacin; Female; Fluoroquinolones; gamma-Aminobutyric Acid; Guinea Pigs; Ileum; Male; Muscle Contraction; Norfloxacin; Quinolizines | 1995 |
Stimulation of genetic instability and associated large genomic rearrangements in Streptomyces ambofaciens by three fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Enoxacin; Gene Amplification; Gene Deletion; Gene Rearrangement; Genome, Bacterial; Humans; Models, Biological; Mutation; Norfloxacin; Pigmentation; Stimulation, Chemical; Streptomyces | 1994 |
In vitro phototoxic activities of new quinolone antibacterial agents: lipid peroxidative potentials.
Topics: Absorption; Anti-Infective Agents; Azides; Ciprofloxacin; Dermatitis, Phototoxic; Enoxacin; Fluoroquinolones; Humans; In Vitro Techniques; Lipid Peroxidation; Norfloxacin; Ofloxacin; Oxygen; Photochemistry; Photosensitivity Disorders; Quinolones; Sodium Azide; Squalene; Ultraviolet Rays | 1994 |
Dissociation and complexation of fluoroquinolone analogues.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Ferric Compounds; Models, Theoretical; Norfloxacin; Ofloxacin; Spectrophotometry | 1994 |
Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
Topics: Biological Transport; Carbon Radioisotopes; Cells, Cultured; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Humans; Intestinal Mucosa; Norfloxacin; Ofloxacin; Pefloxacin; Quinolizines | 1994 |
Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; DNA-Directed DNA Polymerase; Enoxacin; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Gene Expression Regulation, Bacterial; Mutagenicity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolones; Salmonella typhimurium; SOS Response, Genetics; Species Specificity | 1993 |
Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Topics: Aluminum Hydroxide; Animals; Buffers; Chemical Phenomena; Chemistry, Physical; Chloroform; Drug Interactions; Enoxacin; Intestinal Absorption; Levofloxacin; Male; Norfloxacin; Ofloxacin; Phosphates; Rats; Rats, Sprague-Dawley | 1993 |
Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Male; Norfloxacin; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Theophylline | 1993 |
Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Diffusion; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin; Quinolones | 1995 |
Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.
Topics: Anti-Infective Agents; Bacterial Proteins; Base Sequence; Blotting, Northern; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Enoxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutation; Norfloxacin; Plasmids; Polymerase Chain Reaction; RNA, Bacterial; Staphylococcus aureus | 1995 |
[Postantibiotic effects and postantibiotic effects of subinhibitory levels of quinolines on Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Enoxacin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin; Pseudomonas aeruginosa | 1996 |
Intermolecular interactions of antimicrobial fluoroquinolones with purified rat liver CYP1A2 studied by proton nuclear magnetic resonance spectroscopy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cytochrome P-450 CYP1A2; Enoxacin; Fluoroquinolones; Liver; Magnetic Resonance Spectroscopy; Male; Norfloxacin; Phenacetin; Rats; Rats, Wistar | 1996 |
Inhibition of GABAA receptor chloride channel by quinolones and norfloxacin-biphenylacetic acid hybrid compounds.
Topics: Animals; Anti-Infective Agents; Chloride Channels; Chlorine; Enoxacin; GABA Agonists; GABA Antagonists; GABA-A Receptor Antagonists; Male; Muscimol; Norfloxacin; Phenylacetates; Pyridazines; Quinolones; Rats; Rats, Wistar; Synaptosomes | 1996 |
Influence on Pseudomonas aeruginosa elastase, proteinase and alginate by supra-inhibitory and supra-subinhibitory concentrations of quinolones.
Topics: Alginates; Anti-Infective Agents; Endopeptidases; Enoxacin; Microbial Sensitivity Tests; Norfloxacin; Pancreatic Elastase; Pseudomonas aeruginosa | 1996 |
Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative, N-(6,7-difluoroquinolonyl)ampicillin.
Topics: Ampicillin; Ampicillin Resistance; Anti-Infective Agents; Drug Resistance, Microbial; Enoxacin; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Penicillins; Pseudomonas aeruginosa; Pyocins | 1997 |
Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Bicuculline; Brain Chemistry; Cells, Cultured; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Synergism; Enoxacin; Female; GABA-A Receptor Antagonists; Injections, Intraventricular; Male; Membrane Potentials; Mice; Microinjections; Norfloxacin; Oocytes; Phenylacetates; Receptors, GABA-A; RNA, Messenger; Seizures; Xenopus laevis | 1997 |
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Base Sequence; DNA Topoisomerases, Type I; Drug Resistance, Microbial; Enoxacin; Ethidium; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Norfloxacin; Polymorphism, Restriction Fragment Length; Reserpine; Staphylococcus aureus | 1997 |
Hydrophobicity and serum sensitivity of Klebsiella pneumoniae treated with sub-MICs of quinolones.
Topics: Anti-Infective Agents; Blood Bactericidal Activity; Cell Membrane; Ciprofloxacin; Enoxacin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Norfloxacin; Respiratory System; Surface Properties | 1997 |
Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
Topics: Administration, Oral; Adult; Bacteriuria; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross-Over Studies; Enoxacin; Enterococcus faecalis; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Norfloxacin; Proteus mirabilis; Pseudomonas aeruginosa; Random Allocation; Reference Values; Spectrophotometry, Ultraviolet; Time Factors | 1998 |
[Observation of 212 cases of typhoid fever treated with FQNS].
Topics: Adult; Anti-Infective Agents; Child; Ciprofloxacin; Enoxacin; Humans; Norfloxacin; Recurrence; Typhoid Fever | 1997 |
Retention behaviour of quinolone derivatives in high-performance liquid chromatography. Effect of pH and evaluation of ionization constants.
Topics: Acetonitriles; Anti-Infective Agents; Chromatography, High Pressure Liquid; Enoxacin; Fleroxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Norfloxacin; Ofloxacin; Osmolar Concentration; Potentiometry; Quinolizines; Quinolones; Thermodynamics; Water | 1998 |
Photocleavage of DNA by the fluoroquinolone antibacterials.
Topics: Anti-Infective Agents; DNA Damage; Enoxacin; Fleroxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Photolysis; Plasmids; Quinolones; Structure-Activity Relationship; Ultraviolet Rays | 1998 |
Structure and medium-dependent photodecomposition of fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Enoxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Photolysis; Photosensitizing Agents; Quantum Theory; Quinolones; Structure-Activity Relationship | 1998 |
Fluoroquinolone-induced motor changes in the guinea-pig isolated ileum.
Topics: Animals; Anti-Infective Agents; Enoxacin; Female; GABA-A Receptor Antagonists; Gastrointestinal Motility; Guinea Pigs; Ileum; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Norfloxacin | 1998 |
Characterization of quinolone antibacterial-induced convulsions and increases in nuclear AP-1 DNA- and CRE-binding activities in mouse brain.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclic AMP Receptor Protein; Electroencephalography; Enoxacin; Male; Mice; Norfloxacin; Phenylacetates; Seizures; Transcription Factor AP-1 | 1999 |
Effect of suprainhibitory concentrations of quinolones on hydrophobicity and motility of Serratia marcescens.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Movement; Norfloxacin; Serratia marcescens; Virulence | 2000 |
Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
Topics: Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Cohort Studies; Databases, Factual; Drug Monitoring; England; Enoxacin; Family Practice; Female; Humans; Liver Diseases; Male; Middle Aged; Norfloxacin; Ofloxacin; Product Surveillance, Postmarketing; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2001 |
Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials.
Topics: Animals; Anti-Infective Agents; Bone and Bones; Ciprofloxacin; Diphosphonates; Enoxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrogen-Ion Concentration; In Vitro Techniques; Microbial Sensitivity Tests; Norfloxacin; Piperazines; Quinolones; Rats; Spectrometry, Fluorescence; Structure-Activity Relationship; Swine | 2002 |
Effect of enoxacin, norfloxacin and pefloxacin on polymorphonuclear leukocytes chemiluminescence.
Topics: Anti-Infective Agents; Cell Respiration; Enoxacin; Humans; Luminescent Measurements; Neutrophils; Norfloxacin; Pefloxacin | 1991 |
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; beta-Alanine; Biphenyl Compounds; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Convulsants; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Imipenem; Injections, Intravenous; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Norfloxacin; Oxazines; Penicillin G; Quinolones; Seizures; Thienamycins | 2002 |
Laser flash photolysis study of photoionization in fluoroquinolones.
Topics: Anti-Infective Agents; Electron Transport; Enoxacin; Fluoroquinolones; Lasers; Norfloxacin; Photochemistry; Photolysis; Photons; Quantum Theory; Quinolones; Solutions; Time Factors; Water | 2002 |
[Synthesis and antibacterial activity of pyridonecarboxylic acid derivatives containing 2-methyl-5-nitroimidazol].
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Combinatorial Chemistry Techniques; Enoxacin; Escherichia coli; Female; Mice; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles; Norfloxacin | 2003 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enoxacin; Microbial Sensitivity Tests; Norfloxacin; Piperazine; Piperazines; Quinolones | 2003 |
Corneal and scleral permeability of quinolones--a pharmacokinetics study.
Topics: Administration, Topical; Animals; Aqueous Humor; Cell Membrane Permeability; Cinoxacin; Ciprofloxacin; Conjunctiva; Cornea; Enoxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Quinolones; Rabbits; Sclera; Time Factors; Water | 2003 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
HPLC determination of enoxacin, ciprofloxacin, norfloxacin and ofloxacin with photoinduced fluorimetric (PIF) detection and multiemission scanning: application to urine and serum.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Norfloxacin; Ofloxacin; Sensitivity and Specificity; Spectrometry, Fluorescence | 2005 |
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigen-Presenting Cells; Aza Compounds; Cell Proliferation; Cells, Cultured; Ciprofloxacin; Clone Cells; Cross Reactions; Drug Hypersensitivity; Enoxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Delayed; Middle Aged; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Patch Tests; Pipemidic Acid; Quinolines; Quinolones; T-Lymphocytes | 2006 |
Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro.
Topics: Animals; Cell Line; Cinoxacin; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Leishmania guyanensis; Macrophages; Nalidixic Acid; Norfloxacin; Ofloxacin; Quinolones | 2005 |
A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements.
Topics: Anti-Infective Agents; Ciprofloxacin; Electromagnetic Fields; Enoxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Norfloxacin; Protons; Reproducibility of Results; Solutions; Temperature | 2006 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
Formation of secondary triplet species after excitation of fluoroquinolones in the presence of relatively strong bases.
Topics: Anti-Infective Agents; Buffers; Ciprofloxacin; Enoxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Norfloxacin; Oxygen; Photolysis; Solutions; Spectrophotometry; Water | 2008 |
Studies of the photooxidant properties of antibacterial fluoroquinolones and their naphthalene derivatives.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Culture Media; Enoxacin; Escherichia coli; Fluoroquinolones; Histidine; Hydrogen Peroxide; Hydrogen-Ion Concentration; Luminescence; Naphthalenes; Norfloxacin; Oxidants; Oxidants, Photochemical; Photolysis; Photosensitizing Agents; Reactive Oxygen Species; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Ultraviolet Rays | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition.
Topics: Adult; Caffeine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Enoxacin; Humans; Male; Norfloxacin; Reproducibility of Results; Sensitivity and Specificity; Theophylline | 2011 |
The influence mechanism of the molecular structure on the peak current and peak potential in electrochemical detection of typical quinolone antibiotics.
Topics: Anti-Bacterial Agents; Catalysis; Electrochemical Techniques; Enoxacin; Molecular Structure; Norfloxacin; Ofloxacin; Oxidation-Reduction; Quinolones; Water; Water Pollutants, Chemical | 2021 |